Handelsbanken Fonder Ab Cerevel Therapeutics Holdings, Inc. Transaction History

Handelsbanken Fonder Ab

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 05, 2024	BUY	$38.96 - $42.75 $89,608 - $98,325	2,300 Added 14.2%	18,500 $756,000
Q4 2023 Feb 01, 2024	BUY	$20.27 - $42.44 $93,242 - $195,224	4,600 Added 39.66%	16,200 $687,000
Q2 2023 Aug 02, 2023	BUY	$23.9 - $35.38 $62,139 - $91,988	2,600 Added 28.89%	11,600 $369,000
Q3 2022 Oct 27, 2022	BUY	$25.5 - $41.42 $7,650 - $12,426	300 Added 3.45%	9,000 $254,000
Q2 2022 Aug 03, 2022	SELL	$20.62 - $37.15 $32,992 - $59,440	-1,600 Reduced 15.53%	8,700 $230,000
Q4 2021 Feb 08, 2022	BUY	$29.21 - $44.64 $300,863 - $459,792	10,300 New	10,300 $334,000

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

Stay updated on Handelsbanken Fonder Ab with notifications on news.